<< Back To Search

Genetically Engineered Cells (MUC1-Activated T-Cells) for the Treatment of MUC1 Positive Recurrent or Refractory Multiple Myeloma

Notify the Multiple Myeloma Research Foundation You Are Interested In This Trial


Third Opinion Trial Synopsis:
This study looks at using special infection-fighting blood cells called T-cells to fight a type of cancer called multiple myeloma. The study is testing how safe and effective these T-cells are at different doses in patients who have not responded well to other treatments and have a certain protein called MUC1 in their cancer cells. These T-cells are made from the patient's own blood cells and are designed to target the MUC1 protein in cancer cells to help the body's immune system destroy the cancer.
*Third Opinion AI Generated Synopsis

Trial Summary
This phase I trial tests the safety, side effects and best dose of MUC1-activated T cells in treating patients with multiple myeloma that has come back (relapsed) or does not respond to treatment (refractory) and is positive for expression of the MUC1 protein. T-cells are infection fighting blood cells that can kill cancer cells. MUC1-activated T-cells are made from the body's own T cells. The manufactured T-cells are made to target the MUC1 genetic marker and may help the body's immune system identify and kill cancer cells.

Locations & Contact

Fill out the form and "Notify Multiple Myeloma Research Foundation" to let the Multiple Myeloma Research Foundation know you are interested in this trial.

Is There Anything Else You Would Like To Share?